GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » EV-to-FCF

Algernon Pharmaceuticals (XCNQ:AGN) EV-to-FCF : -2.10 (As of May. 25, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Algernon Pharmaceuticals's Enterprise Value is C$3.42 Mil. Algernon Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2024 was C$-1.63 Mil. Therefore, Algernon Pharmaceuticals's EV-to-FCF for today is -2.10.

The historical rank and industry rank for Algernon Pharmaceuticals's EV-to-FCF or its related term are showing as below:

XCNQ:AGN' s EV-to-FCF Range Over the Past 10 Years
Min: -2.36   Med: 0   Max: 0
Current: -2.1

XCNQ:AGN's EV-to-FCF is ranked worse than
100% of 367 companies
in the Biotechnology industry
Industry Median: 9.77 vs XCNQ:AGN: -2.10

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Algernon Pharmaceuticals's stock price is C$0.16. Algernon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.340. Therefore, Algernon Pharmaceuticals's PE Ratio for today is At Loss.


Algernon Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Algernon Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals EV-to-FCF Chart

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -3.22 -5.89 -1.80 -3.70 -0.95

Algernon Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.03 -0.78 -0.95 -0.60 -0.95

Competitive Comparison of Algernon Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Algernon Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algernon Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's EV-to-FCF falls into.



Algernon Pharmaceuticals EV-to-FCF Calculation

Algernon Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=3.418/-1.63
=-2.10

Algernon Pharmaceuticals's current Enterprise Value is C$3.42 Mil.
Algernon Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algernon Pharmaceuticals  (XCNQ:AGN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Algernon Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.16/-0.340
=At Loss

Algernon Pharmaceuticals's share price for today is C$0.16.
Algernon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.340.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Algernon Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals (XCNQ:AGN) Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.
Executives
Christopher Moreau Director, Senior Officer

Algernon Pharmaceuticals (XCNQ:AGN) Headlines

No Headlines